Stock TMO THERMO FISHER SCIENTIFIC INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Thermo Fisher Scientific Inc. Buenos Aires S.E.

Equities

TMO

ARBCOM4601F7

End-of-day quote Buenos Aires S.E.
Other stock markets
 18:00:00 2024-05-30 EDT 		5-day change 1st Jan Change
32,090 ARS +3.21% Intraday chart for Thermo Fisher Scientific Inc. -1.65% +37.17%
05-31 Thermo Fisher Scientific Updates Chromosomal Microarray Analysis Solutions to Comply with IVDR Regulation CI
05-24 Declaration of Voting Results by Thermo Fisher Scientific Inc CI

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • The company returns high margins, thereby supporting business profitability.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company is in debt and has limited leeway for investment
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 35.67 times its estimated earnings per share for the ongoing year.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

1st Jan change Capi. Investor Rating ESG Refinitiv
THERMO FISHER SCIENTIFIC INC. Stock Thermo Fisher Scientific Inc.
+37.17% 217B -
DANAHER CORPORATION Stock Danaher Corporation
+11.01% 190B
B-
INTUITIVE SURGICAL, INC. Stock Intuitive Surgical, Inc.
+19.20% 143B
B-
BOSTON SCIENTIFIC CORPORATION Stock Boston Scientific Corporation
+30.79% 111B
A-
SIEMENS HEALTHINEERS AG Stock Siemens Healthineers AG
+1.48% 64.59B
A-
EDWARDS LIFESCIENCES CORPORATION Stock Edwards Lifesciences Corporation
+13.95% 52.36B
B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD. Stock Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
-0.16% 48.45B
B+
AGILENT TECHNOLOGIES, INC. Stock Agilent Technologies, Inc.
-6.20% 38.03B
A
GE HEALTHCARE TECHNOLOGIES INC. Stock GE HealthCare Technologies Inc.
+0.91% 35.61B -
RESMED, INC. Stock ResMed, Inc.
+19.95% 30.31B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TMO Stock
  4. TMO Stock
  5. Ratings Thermo Fisher Scientific Inc.